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ABSTRACT
Although poorly understood, normal cells and cancerous cells of the same type exhibit
different patterns of nutrient consumption, processing and utility of metabolic substrates.
Differences in substrate uptake, preference, and alternately emphasized metabolic pathways offer
opportunities for selective targeting of cancer versus stroma. This may be accomplished by
using a sequential approach of nutrient deprivation and pharmaceutical perturbation of metabolic
pathways to inhibit cellular proliferation. The purpose of this study was to investigate the effects
of restricting glucose and glutamine concentrations, in vitro, to levels that resemble a potential
human fasting state. The mammalian target of rapamycin (mTOR), a mediator of nutrient
sensation, was then inhibited with rapamycin in the nutrient-restricted conditions. Because
active Akt/mTOR is implicated in cancer cell pro-survival, the hypothesis is that pharmaceutical
inhibition of active Akt/mTOR signaling in combination with the stress of restricted nutrient
supply will be more effective than nutrient deprivation alone at disrupting metabolic processes to
impair cancer cell proliferation and/or pro-survival mechanisms. Untreated and treated
conditions were tested to determine if an additive or synergistic effect would result from a
sequential insult of nutrient deprivation followed by inhibited mTORC1 signaling.
The cell line used for this study was cultivated from a murine pancreatic intraepithelial
neoplasia (PANIN) derived from a transgenic mouse with pancreatic tissue-specific expression
of constitutively active Akt. The transgene of Akt, isoform 1, contains a myristoyl tag that
facilitates co-localization of Akt to the plasma membrane, thereby promoting the activation of
this signaling protein. This aberrantly activated Akt represents a prosurvival condition observed
iii

in most cancers, and impacts metabolic balance with increased downstream signaling to
metabolic sensors and regulators, including mTORC1.

Several methods were used to evaluate changes in metabolic and physiological response
to nutrient deprivation and mTORC1 inhibition. These included tetrazolium
reduction/absorbance readings to qualitatively evaluate differences in cell proliferation, and
Western immunoblots for observing changes in protein expression and phosphorylation. ATP
luminescence assays were applied to quantify intracellular ATP content, and citrate synthase
spectrophotometry used to quantify specific activity/indicate changes in the TCA/OXPHOS
production of ATP. Results from the above methods suggest that, individually, nutrient
deprivation and rapamycin treatment share some similar effects on metabolically-related protein
phosphorylation and in reducing cellular proliferation. Collectively, nutrient deprivation plus
rapamycin treatment, however, resulted in unanticipated metabolic alterations under conditions
used for this study, the complexities of which would need to be delineated in future studies.
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CHAPTER ONE: INTRODUCTION
Metabolism encompasses the totality of chemical transformations that comprise the
energetic and material basis for cellular life. This totality can be subdivided into two categories
of activity: catabolism, or energy production, and anabolism, component production. Cellular
respiration refers to the set of catabolic or energy-producing chemical transformations whereby
metazoan cells convert organic compounds into the energy currency of the cell, adenosine
triphosphate (ATP) and byproducts. Cellular respiration proceeds through a series of enzymatic
pathways in order to process substrates into biochemical energy; the first of these pathways is
termed glycolysis1.

Glycolysis

Glycolysis is an oxygen-independent metabolic pathway that consumes carbohydrates,
particularly glucose, as the substrate for energy production. This process occurs in the
cytoplasm, and is comprised of a series of ten enzymatic reactions that convert one molecule of
carbohydrate into two pyruvate molecules, reduce two nicotine adenine dinucleotide (NADH)
coenzymes and generate two molecules of ATP. The resulting pyruvate molecules then have
two potential fates, depending on whether molecular oxygen (O2) is present. In conditions where
a sufficient concentration of O2 is present in the intracellular space, the pyruvate can be
transported into the mitochondria and oxidized into acetyl-CoA and CO2, a transition step that
links the metabolic pathways of glycolysis and the tricarboxylic acid cycle (TCA). Alternately,
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in hypoxic, or low O2 concentration, or anoxic conditions where no O2 is present, the pyruvate
can be converted into lactic acid via a process termed lactic acid fermentation1.

Tricarboxylic Acid Cycle/Oxidative Phosphorylation

The TCA is comprised of a cyclic series of eight enzymatic reactions, a process that
occurs in the matrix of the mitochondria. These reactions convert one molecule of acetyl-CoA
into two molecules of CO2 and H2O, and subsequently reduce three molecules of NAD+ to
NADH and one molecule of ubiquinone (Q) to ubiquinol (QH2). These reduced coenzymes then
transfer their electrons into the oxidative phosphorylation (OXPHOS) pathway. As the
coenzymes release electrons into the electron transport chain (ETC) of the OXPHOS pathway, a
proton gradient is established across the cristae membrane in the mitochondria. The potential
produced by the proton gradient yields a proton motive force that drives the formation of ATP
from adenosine diphosphate (ADP) and inorganic phosphate via the ATP synthasome2,3.
Oxygen couples TCA and OXPHOS by accepting the electrons generated by TCA which are
transported through the electron transport chain of OXPHOS; O2 is reduced and converted to
H2O at the terminus of the ETC. Thus, oxygen ultimately receives the electrons transferred from
the carbohydrate substrate, and fundamentally links the metabolic pathways of glycolysis, TCA
and OXPHOS in a process referred to as aerobic respiration3.

In hypoxic or anoxic conditions, insufficient O2 inhibits the efficient consumption of
pyruvate via aerobic respiration; in such anaerobic conditions, anaerobic respiration results. In
2

conditions where pyruvate accumulates, the redox state of the cell changes due to the
corresponding concentration increase of NADH and decrease of NAD+. To restore the redox
state, the accumulated pyruvate requires conversion by lactic acid dehydrogenase and NADH
into lactic acid via lactic acid fermentation1.

In normal cells, the constituent pathways of aerobic respiration, glycolysis, TCA and
OXPHOS are tightly coupled. Carbohydrates are first consumed through the energetically lowyield glycolysis, and the end product of pyruvate then processed through TCA/OXPHOS for a
high yield of ATP1,3. In conditions of hypoxic exertion or anoxic ischemia, anaerobic respiration
uses lactic acid fermentation to continue a reduced production of biochemical energy. Cancer
metabolism, however, differs markedly from normal cellular metabolism, and demonstrates
different rates and activity of the catabolic and anabolic pathways versus normal cells of the
same type4.

Warburg Effect

Metabolic differences between normal and cancerous tissues were reported in 1924 by
Otto Warburg et al. Warburg used a manometer to quantify oxygen consumption in thin slices of
tissue. The manometer was additionally equipped to measure carbon dioxide (CO2) emission,
which correlated to lactic acid (C3H6O3) production in a bicarbonate (HCO3-) buffer according to
the formula: C3H6O3 + HCO3-  C3H5O3- + H2O + CO2. Results from the manometric
measurements indicated that cancerous tissue generated lactic acid even in aerobic, or
3

oxygenated conditions5, 6. The generation of lactic acid in aerobic conditions, due to the
conversion of pyruvate, indicated a deregulation of either glycolysis or OXPHOS.

The measured O2 consumption, however, was determined to be the same in the normal
and cancerous tissues. Despite these results, Warburg asserted:

“The origin of cancer lies in the anaerobic metabolic component of normal growing cells,
which is more resistant to damage than is the respiratory component. Damage to the
organism favours this anaerobic component and, therefore, engenders cancer.6,7”

Thus, Warburg hypothesized that the aerobic production of lactic acid was related to a damaged
respiratory system (TCA/OXPHOS). Later studies have correlated instances of aerobic
glycolysis with mitochondrial damage or depopulation; such instances, however, do not account
for deregulation of the glycolytic pathway, a possibility Warburg discounted6,8,9.

Evidence for a cancerous metabolic shift in favor of glycolysis was supplied by a
genomic study of a set of 24 cancers, representing greater than 70% of human cancer cases
globally. The authors state, “in glycolysis the overexpression of genes is the rule rather than the
exception,” finding 62% of possible overexpressions of genes in the glycolysis pathway were
indeed overexpressed10. Reliance of cancerous cells on the low ATP-yielding glycolysis
pathway in contradistinction to the higher ATP-yield of aerobic respiration appears paradoxical;
however, the rate of ATP production from glycolysis is approximately 100 times faster than from
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oxidative phosphorylation11. Warburg described the difference between the metabolic emphases
of cancerous versus normal cells:

“This converted to energy equivalents means that the cancer cells can obtain
approximately the same amount of energy from fermentation as from respiration whereas
the normal body cells obtain much more energy from respiration than from
fermentation12”

The comparatively rapid rate of glycolysis versus TCA/OXPHOS supplies cancer cells with a
competitive advantage versus normal cells for a shared energy resource, glucose11. Despite
relative energy production equivalence, in the cancerous metabolic condition where lactic acid
fermentation is not suppressed by the presence of O2, additional metabolic byproducts are
produced by the glycolytic pathway. These byproducts are processed by the pentose phosphate
pathway, supplying precursors for the biosynthesis of nucleic acids, phospholipids, fatty acids,
cholesterol, and porphyrins13. Upregulated glycolysis, and consequently precursor byproducts,
promotes an increased supply of cellular components and facilitates proliferation. Another
additional benefit conferred by the cancerous reliance on glycolysis consists of the reduced
cellular requirement for O2, an important protection in conditions of ischemia produced by
rapidly proliferating cells13.
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Deregulated Glycolysis

Enzyme isoforms in the cancerous glycolytic pathway exert disproportionate influence on
the transfer of intermediates into accessory processing pathways, as well as the overall reaction
rate of glycolysis. Deregulated activity of the glycolytic pathway appears to be mostly
attributable to isoforms of two enzymes, one at the beginning of the pathway, the other at the
end. Hexokinase (HK), the first enzyme in the glycolytic pathway, phosphorylates glucose
according to the formula: Glucose + ATP → Glucose-6-PO24- + ADP1,14. This reaction
accomplishes a dual function in maintaining a low intracellular concentration of glucose while
preventing the export of the phosphorylated carbohydrate product from the intracellular space15.

Hexokinase

Four isoforms of HK have been identified in mammalian tissue, denoted HK I, HK II,
HK III, and HK IV (also termed glucokinase). Tissues such as liver and pancreas express HK IV
under normal conditions; this particular isoform has a much higher Km (~5mM) than the Km of
HK I, II and III (~0.02mM). Thus HK I, II and III demonstrate an affinity for substrate 250
times greater than HK IV, increasing the relative reaction rate whereby glucose is
phosphorylated. HK isozymes are expressed depending on cellular conditions: HK I mediates
the phosphorylation of glucose in non-dividing cells, alternately, HK II is induced and performs
the same function in proliferating cells; in tumorigenesis of liver and pancreatic tissues, a
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“switch-over” of HK IV to HK II occurs, with a corresponding silencing of HK IV (glucokinase)
expression15,16,17,18.

The hexokinase isozymes localize differently in the cell, with glucokinase localized in the
nucleus in complex with the glucokinase regulatory protein (GKRP). Increases in intracellular
glucose concentrations in hepatocyte and pancreatic β-cells result in HK IV-GKRP disassembly
and translocation of HK IV to the cytoplasm, where the enzyme attaches to insulin granules, with
a small fraction of HK IV possibly associating with outer mitochondrial membranes19,20,21. No
evidence for a regulatory protein of either HK I or II has been documented; these hexokinases
also preferentially populate the outer mitochondrial membrane, binding to the voltage dependent
anion channel (VDAC)22. Binding to the mitochondrial membrane by HK I & II facilitates
substrate channeling of intra-mitochondrially generated ATP to the hexokinase23,24. HK I & II
translocation and binding to the mitochondrial membrane also reduces the sensitivity of the
isoenzymes to allosteric inhibition by their product glucose-6-phosphate (G6P)25, 26. Thus, four
factors, the absence of a specific regulatory protein, a lower Km compared to glucokinase,
localization to a source of substrate, and reduced product inhibition generate an advantageous
combination for HK II to disrupt the dynamic balance between glycolysis and TCA/OXPHOS.

Pyruvate Kinase

The enzyme responsible for catalyzing the final step of glycolysis is pyruvate kinase
(PK). This transferase catalyzes the transfer of a phosphoryl from phosphoenolpyruvate to ADP,
7

generating one ATP and one molecule of pyruvic acid. Just as a variety of hexokinase isozymes
are expressed depending on cellular conditions, pyruvate kinase has tissue-specific isoforms such
as PKL, found in gluconeogenic tissues such as liver and kidneys, PKR, found in erythrocytes, as
well as pyruvate kinase M isoform 1 (PKM1), found in metabolically demanding tissues such as
muscle and brain27. Pyruvate kinase isoform 2 (PKM2) has been observed to be expressed in
normal differentiated tissues, including fat, lung and retinal, as well as pancreatic islets28. PKM2
has been characterized as the isoform expressed in cells with high rates of nucleic acid synthesis,
i.e. proliferating cells. The expression of PKM2 is thus found almost universally in proliferating
cells, though not necessarily the exclusive isoform present, in normal and embryonic tissues,
with higher expression of this splice variant found in cancerous cells27.

Non-proliferating, differentiated cells rely on the efficient ATP generation of
TCA/OXPHOS, a catabolic optimization of bioenergetic precursors in competitive metazoan
conditions of limited growth factor supply29. Proliferating cells, alternatively, depend less on
maximization of ATP yield and instead emphasize metabolic intermediate/precursor flux into
anabolic pathways30. One means of this precursor diversion into macromolecular synthetic
pathways is driven by the expression the glycolytic isoform HK II, which generates the
metabolic intermediate glucose-6-phosphate (G-6-P) at a greater rate due to mitochondrial
localization and faster reaction rate. PKM2 also facilitates anabolic metabolism via a switchable,
reduced reaction rate versus PKM1, promoting the accumulation of upstream glycolytic
intermediates, which are then shunted to anabolic pathways branching from the glycolytic
pathway30.
8

Unlike PKM1, which exists solely as a highly enzymatically active tetramer, PKM2 has
two forms: a tetramer with high affinity for phosphoenolpyruvate (PEP), and a dimer with low
PEP affinity31. The PKM2 tetramer:dimer ratio determines the direction of substrate flux: when
the tetramer predominates, PEP is converted to pyruvate, available for lactic acid fermentation or
TCA/OXPHOS; in contrast, the enzymatically inactive dimer introduces a glycolytic bottleneck,
requiring the shunting of glycolytic intermediates into branching synthetic pathways31.
Byproducts of the branching synthetic pathways, such as reactive oxygen species (ROS)
generated from the pentose phosphate pathway, inactivate the PKM2 tetramer32. Additional
down-regulatory mechanisms for PKM2 have been found, including inhibition of tetramer
formation due to tyrosine phosphorylation (Y105), and chaperone-mediated autophagy via
acetylation of a specific lysine (K305) on PKM2 in high glucose environments33,34. As a result,
PKM2 function oscillates depending on tetramer:dimer ratio, controlled by ROS and
phosphotyrosine inactivation, as well as context-dependent degradation. PKM2 thus provides
the proliferating cell a responsive, regulatory switch between energy maximization and anabolic
synthesis in the glycolytic phenotype29,30,31.

Akt

The Akt kinase family functions as a downstream effector of growth factor signaling
pathways, and is activated by membrane bound phosphoinositol-3-kinase (PI3K)-dependent
mechanisms. Akt is a serine/threonine kinase, expressed as three isoforms, and has been
documented as frequently hyperactivated across a broad variety of tumor types35,36. Akt exerts
9

pleiotropic effects that can facilitate tumorigenesis and cancer cell survival, modulating
proliferation, prosurvival mechanisms and intermediate metabolism35,37. Of the three isoforms,
Akt1 and Akt2 appear particularly relevant to the processes of cancer metabolism and survival.

Hyperactivity of Akt in cancer has been associated with increased glycolysis, in part due
to increased expression levels of GLUT1 and inducing increased translocation of GLUT4 to the
plasma membrane39,43. Additionally, Akt activation has been demonstrated to increase the
binding of hexokinase to the mitochondria40. Akt can directly phosphorylate hexokinase II; this
phosphorylation has been demonstrated in cardiomyocytes to increase the binding of HK II to the
voltage dependent anion channel (VDAC) in the outer mitochondrial membrane39.

Another metabolic regulation effected by Akt results from Akt phosphorylating glycogen
synthase kinase 3 beta (GSK3β) on serine 9, inactivating GSK3β38. This inactivation is
significant in the coupling of glycolysis and TCA/OXPHOS as GSK3β phosphorylates the
VDAC, which occludes the binding site for HK II, preventing hexokinase binding to the
mitochondrial membrane. Upregulated AKT activity increases the inhibitory phosphorylation of
GSK3β, facilitating the binding of HK II to the mitochondrial membrane38. The Akt-mediated
binding of HK II to the mitochondrial membrane directs HK II activity in favor of glycolysis,
due largely to the channeling of the intra-mitochondrial ATP to HK II as well as the reduced
sensitivity of HK II to the inhibitory product G-6-P when attached to the mitochondrial
membrane23,24. An additional prosurvival effect is obtained by having HK II bind the VDAC,
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preventing the closure of the VDAC and thereby inhibiting the formation of the mitochondrial
transition pore in response to stress and hypoxic conditions38.

Using polymerase chain reaction, genes that encode for an Akt have been modified with a
src myristoylation sequence, which have been transfected into specialized mouse lines via
recombinant DNA technology42. Myristoylated Akt (mAkt) demonstrates constitutive activity in
cellulo, as the myristoyl facilitates Akt adhesion to the plasma membrane, promoting the dual
phosphorylation required for full activation of the kinase43. Constitutive Akt activity decouples
the cell from dependence on growth factor-initiated signal transduction, inducing an autonomous
proliferative signaling cascade30. Additional metabolic changes attributable to
mAkt/hyperactivated Akt beyond increased glucose flux include constitutive lipogenesis (a
building block for necessary for proliferation) and enhancement of insulin-stimulated glycogen
synthesis, due to Akt-mediated inhibition of GSK3β43.

Akt also promotes cell growth by facilitating the activation of the mammalian target of
rapamycin (mTOR). This facilitated activation results from Akt-mediated phosphorylation of
negative regulators of mTOR, including tuberous sclerosis complex 2 (TSC2) and the prolinerich Akt substrate of 40kDa (PRAS40)44,45. Phosphorylation of TSC2 promotes complexation
with TSC1, which together act as a GTPase-activating protein for the Rheb protein, which
activates mTOR complex 1 (mTORC1) when Rheb has GTP bound44,46. PRAS40 associates
with mTORC1 and has been found to negatively regulate mTORC1 signaling; phosphorylation
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of PRAS40 by Akt inhibits the negative regulation imposed by PRAS40 when in complex with
mTORC144,47.

mTOR

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that integrates
inputs from energy status signals, oxygen and amino acid concentrations, as well as growth
factor signaling downstream from Akt, functioning as a switch for anabolic and catabolic
processes48. mTOR nucleates two distinct multiprotein complexes, referred to mTOR complexes
1 and 2 (mTORC1, mTORC2).

mTOR acts as the master negative regulator in an essential process of cell regulation and
survival, autophagy52. mTOR complex 1 integrates nutrient availability and growth factor
signals, mediating the balance between cell growth and autophagy. Given nutrient-sufficient
conditions, mTORC1 inactivates the nucleation of phagophores, thereby repressing the
autophagic process. In restricted nutrient conditions, however, mTORC1 activity becomes
inhibited, which de-suppresses autophagy, allowing the cell to mobilize intracellular resources
through decomposition of proteins and organelles to cellular building blocks53.

Conditions of glucose starvation reduce the intracellular ratio of metabolically generated
ATP versus adenosine monophosphate (AMP); increases of AMP concentration relative to ATP
can result in the activation of the energy status sensor 5' adenosine monophosphate-activated
12

protein kinase (AMPK), depending on the cell type. In particular, glucose sensing cells that
express the glucose transporter GLUT2 and glucokinase, such as pancreatic beta cells, AMPK is
regulated by fluctuations in available glucose55. Activated AMPK inhibits mTORC1 by
phosphorylation/activation of TSC2, which, in activated state, negatively regulates mTORC1.
AMPK also inhibits mTORC1 via direct phosphorylation mTORC1-associated protein Raptor.
Just as mTOR negatively regulates autophagy, the negative regulation of mTORC1 by AMPK
corresponds to a positive regulation of autophagy53,54,55.

mTOR also plays a key role in translation of mRNA, functioning as an anabolic regulator
sensitive to amino acid concentrations60. This role is fulfilled by transducing growth factor
signaling from Akt to ribosomal protein kinase S6 kinase (S6K) and the eukaryotic translation
initiation factor 4E (eIF4E)-binding proteins (4E-BP1, 2, 3)56,58. 4E-BP1 is
phosphorylated/inactivated by mTORC1, which induces the disassociation of the binding protein
from the eIF4E. The released translation initiation factor is then free to bind eIF4G, which
commences protein translation57,58.

Inhibition of mTORC1 via rapamycin prevents downstream phosphorylation/activation of
S6K, and consequently ribosomal protein S6 (rpS6). Inhibition of rpS6 induces a partial
inhibition of translation initiation of 5’ terminal oligopryimidine tract (5’TOP) mRNAs,
attributable to a reduction in the inactivated rpS6’s affinity for 5’TOP mRNAs59. Consequently,
partial inhibition of the 5’TOP mRNAs via rapamycin inhibition of mTORC1 signaling results in
a reduction of protein translation. Phosphorylation/dissociation of 4E-BP1 from eIF4E also
13

demonstrates a decremental response to rapamycin-mediated inhibition of mTORC1,
contributing to a reduction in dissociated eIF4E and consequently protein translation61. Notably,
the effect of rapamycin on inhibition of mTORC1appears to depend on concentration, with S6K
suppressed at nanomolar doses, and eIF4E at micro-molar doses61,62.

The Akt/mTOR pathway is activated by growth factors such as insulin and insulin-like
growth factor 1 (IGF1), which bind both insulin and IGF1 receptors. These activated receptors
then phosphorylate insulin receptor substrates 1 and 2 (IRS1, 2), which transduce signal to Akt
via PI3K. Activated Akt via IRS1,2 then indirectly activates mTOR through TSC2 and PRAS40
phosphorylation. Activation of mTOR consequently mediates a feedback down-regulation of the
PI3K/Akt/mTOR pathway by inducing a loss of IRS1 expression through S6K49. In conditions
of nutrient satiety, S6K is activated, which has been shown to negatively regulate insulin
signaling; this down-regulation facilitates the suppression of insulin signaling through IRS
phosphorylation by S6K, ultimately traceable to mTORC1 activity51. Alternately, in conditions
of mTOR inhibition via rapamycin, IRS1 protein levels have been found in a number of tumor
cell lines to be upregulated, which induces Akt phosphorylation and consequent upregulation of
Akt kinase activity49.

The Mitochondrion

The mitochondrion is an organelle composed of a permeable outer membrane, perforated
by porins, and an impermeable inner membrane. The inner membrane of the mitochondrion
14

contains the mitochondrial matrix, wherein the enzymes of the TCA cycle oxidize acetyl-CoA to
CO2, generating GTP, NADH and FADH2. The reduced coenzymes NADH and FADH2 provide
the electrons and protons for perpetuating the OXPHOS electronic and protonic gradients. The
electrons are transported through four complexes in the electron transport chain, ensconced in the
inner mitochondrial membrane, and ultimately reduce molecular oxygen into water. The protons
from the coenzymes are transported across the inner mitochondrial membrane; the gradient then
refluxes through the ATP synthasome to generate ATP from ADP and inorganic phosphate3,63,64.

mTOR has been implicated in coordinating mitochondrial activity with growth
regulation. A study examining the effect of mitochondrial dysfunction on mTOR found that
mTOR was largely co-localized with the outer membrane of the mitochondria65. Another study
using Jurkat cells determined that the inhibition of mTORC1 using rapamycin resulted in
decreases in mitochondrial membrane potential, reduced oxygen consumption and overall
oxidative capacity, fundamentally altering the metabolic rate of the treated cells66. Schieke et al.
discovered that mTORC1 inhibition did not induce significant changes in the expression levels
of OXPHOS-associated proteins. The OXPHOS-associated proteins, however, exhibited
isoelectric shifts indicative of dephosphorylation in the rapamycin-inhibited conditions.
Conservation of protein expression in tandem with dephosphorylation in mTORC1-inhibited
conditions indicates an mTOR-mediated regulation of the OXPHOS phosphoproteome66.
Mitochondrial function can also influence mTOR activity via a process termed retrograde
signaling; this reciprocal regulation by mitochondria can issue a down-regulatory signal to
mTOR in the event of lowered membrane potential65,66,67,68.
15

Ramanathan and Schreiber discovered an immediate change in mitochondrial function
after inhibition of mTOR. Rapamycin-treated leukemic cells were observed to demonstrate
reduced mitochondrial function, with a corresponding upregulation of aerobic glycolysis; these
changes were tracked within a 25 minute experimental window69. Notably, the authors observed
an increase of amino acid concentrations, including arginine, histidine, proline, isoleucine,
methionine, valine, phenylalanine and tyrosine, all of which may be converted to TCA cycle
intermediates via the process of anaplerosis. Additionally, immunoprecipitations performed as
part of the study revealed that mTOR co-immunoprecipitates with the mitochondrial VDAC and
Bcl-xl. mTOR therefore appears to be integrally connected with mitochondrial function,
particularly with respect to the VDAC, also a binding site for HK II22,69.

Nutrient Restriction

Hirayama et al. conducted a metabolomics analysis of human colon and gastric cancers,
finding very low glucose and correspondingly high lactate and glycolytic intermediate
concentrations70. Intratumoral tissue amino acid concentrations were also found to be elevated,
with glutamate present in the highest concentrations. Glutamine, however, was determined to be
at levels near normal tissues. The excess of glutamate indicated a high flux of glutamine
consumption, as cancer cells frequently act as “nitrogen traps”, competing against the host for
glutamine to oxidize and for protein synthesis69. Glutamine is secondary only to glucose in
cancer cell metabolism; it has the highest concentration of any amino acid in human plasma, and
cancer cells metabolize more glutamine than any other amino acid72,73,74.
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Poor vascularity and upregulated amino acid biosynthesis insufficiently accounted for the
excess essential amino acid concentrations in the tumors studied; evidence for autophagy was
indicated by excesses of hydroxyproline, a byproduct of autophagic degradation of collagen70.
Indeed, activated autophagy has been associated with pancreatic cancer cells as a response to
poor vascularization, with the attendant effects of hypoxia and nutrient insufficiency72.

Rationale and Hypothesis

The flux of nutrients available to cancerous cells affects the metabolic mechanisms
emphasized for growth, proliferation and survival70,71,75,76. Nutritional context also impacts the
effect of anticancer agents on cancerous cells; an in vitro study by Lu et al. found vincristine, 5fluorouracil, taxol, doxorubicin, cisplatin, and camptothecin killed human cancer cell lines in
nutrient sufficient media, but exerted significantly reduced cytotoxicity in nutrient-restricted
media77. Since nutrition can impact cancer metabolic mechanisms and anticancer drug
effectiveness, it may offer a leveragable variable to target and damage cancerous cells versus
normal cells.

The PI3K-Akt-mTOR pathway provides the cell with essential signaling with respect to
growth, proliferation and cell survival. However, this pathway may be converted to a pro-death
signal, driving cells to necrosis or nonapoptotic cell death in response to metabolic stress.
Activation of PI3K/Akt via insulin and IGF-1 in glucose restricted contexts has been
demonstrated to result in inhibition of autophagy and consequent autophagic cell death in rat
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cardiomyocytes78. Wu et al. have supplied further evidence for the mechanism of activated
PI3K-Akt-mTOR signaling suppressing the prosurvival effects of autophagy and promoting
necrotic cell death in cells subjected to starvation conditions79.

The cells used for this experimental inquiry were harvested from a murine pancreatic
lesion; this cell line is remarkable in that the specimen was culled from a transgenic mouse,
expressing an ectopic myristoylated Akt1 (mAkt1) in its pancreatic tissues. The presence of this
ectopic mAkt1 induces a condition of constitutive Akt1 activation, due to the membrane
recruitment facilitated by the myristoyl modification. This state of constitutive activation
provides a simulated context for the majority of cancer cells that exhibit hyperactivated Akt35,36.

Cells that express activated Akt exhibit enhanced proliferation and upregulated nutrient
intake. Cancerous cells, likewise, develop competitive metabolic phenotypes, relative to normal
cells, that support proliferative modalities. Cancerous cells quickly generate a nutrient-deprived
context, relative to normal tissues, due to the de-regulated proliferation generated by the
competitive metabolic phenotypes. Indurated tumor mass formation creates a context
characterized by deprivation of vascular delivery of O2, glucose, amino acids and growth factors.
Thus the cells comprising the tumor mass adapt to a situation of nutritional insufficiency,
adopting phenotypes that optimize energy and cellular building block production from metabolic
intermediates.
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The original research proposal consisted of two conceptual parts. The first part of the
original concept involved a comparative set of experiments to evaluate cell line response to
restricting the essential nutrients glutamine and glucose. Growth media was compared to two
minimal media preparations, one with glucose concentrations equal to growth media, and one
that approximated human physiological fasting glucose concentrations. Both minimal media
preparations had reduced glutamine concentrations, relative to growth media, and approximated
human physiological fasting levels of glutamine. The rationale behind the reduction of nutrient
supply was to determine if inducing a fasting state would impose a cytostatic, autophagic or
apoptotic response in the cell lines. By extension, nutrient restriction in vivo would further
reduce the already restricted nutrients supplied to cancerous cells in tumor formation.

The second main part of the original proposal concept involved mTOR inhibition via
rapamycin. The thrust of this inquiry was inspired by a study performed by Lashinger et al.,
comparing differences in pancreatic tumor formation in mice treated with dietary versus
pharmacologic interventions. Results from the study found that both chronic calorie restriction
and rapamycin-mediated inhibition of mTOR decreased pancreatic tumor growth; however,
calorie restriction was associated with reductions in prosurvival signaling, while rapamycin
treatment did not mimic this effect. Calorie restriction (CR) in the mice was found to result in
pleiotropic effects, inducing systemic reductions in circulating hormones IGF-1 and leptin
production, while also reducing tumor cell expression of phospho-Akt , mTOR and IGF-1R80.
Contrarily, selective inhibition of mTOR with rapamycin did not significantly impact hormonal
production versus controls.
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In cells with an activated Akt condition, mTOR inhibition removes regulatory repression
of autophagy, with indications that the cell compensates for mTOR inhibition by up-regulating
IGF-1R and IRS-1. Upregulation of this receptor and key signaling enzyme increase the cellular
capacity for the uptake of growth factors, which activate the PI3K-Akt-mTOR pathway. As
activated Akt has the potential to act as a pro-death signal, a combined treatment including
mTOR inhibition and nutrient restriction may lever the pathway away from prosurvival activity,
leading instead towards necrosis.

Restricting nutrients imposes a condition of metabolic stress on the cell; pancreatic
cancer cells have previously been demonstrated to include autophagy as an integral contribution
to the proliferative metabolic repertoire72. When the cell is already in a condition where it relies
on autophagy for survival in conditions of reduced nutrient supply, excess reliance imposed by
severe nutritional restriction may further contribute to the induction of a necrotic process.
Rapamycin treatment removes the regulatory suppression of autophagy, which may accelerate
autophagic processes in conditions of metabolic stress. Integrating the concepts of nutrient
restriction, to induce metabolic stress, in combination with rapamycin treatment, to de-suppress
or increase the activity of autophagy, generated the hypothesis of this study: a combination
treatment of nutrient restriction and rapamycin inhibition will exert an additive or synergistic
cytostatic/cytotoxic effect in vitro on the mAkt1 pancreatic neoplasia cell line. In support of this
hypothesis, Sun et al. achieved synergistic reductions in the proliferation and tumor development
of cells with hyperactive mTOR by employing a strategy of dual suppression of mTOR and
glycolysis using rapamycin and 3-bromopyruvate80.
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One of the mechanisms used for the support of this hypothesis was driven by
Ramanathan and Schreiber’s discovery that mTOR inhibition with rapamycin induced immediate
changes in mitochondrial function, with energetic production shunted from mitochondrial to
glycolytic mechanisms69. This metabolic shift may possibly be linked to mTOR functioning as a
positive regulator for the glycolytic isoenzyme PKM2; paradoxically, however, hyperactive
mTOR has been correlated with promotion of aerobic glycolysis81. As Ramanathan and
Schreiber constrained their metabolic assays to the immediate and 25-minute post incubation
with rapamycin responses, their results may indicate a transitional phase of metabolic
readjustment. An experimental model that includes pre-conditioning to new nutritional
concentrations, followed by assays taken after a more extended incubation with rapamycin was
consequently developed for this project. Extending the interval of treatment provides data that
indicates the stability of the immediate and short-term metabolic changes observed by
Ramanathan et al.
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CHAPTER TWO: MATERIALS AND METHODS
Cell Culture

A transgenic murine cell line cultured from a pancreatic lesion, and expressing mAkt1
(P177), was used for all following experiments. The cells were cultured in growth media
consisting of Dulbecco’s Modified Eagle’s Medium (DMEM, Corning Cellgro) with 100 U/mL
penicillin, 100 μg/mL streptomycin, 2mM glutamine and 10% fetal bovine serum (FBS, Atlanta
Biologicals) added, in 5% CO2 AT 37 C.

Nutrient Restricted Media

Minimal media first prepared using 900mL of deionized water added to a 1000mL
beaker, with 1 vial of Dulbecco’s Modified Eagles Base powder (Sigma, D5030). 3.7g of
sodium bicarbonate were added, and pH adjusted using 1M NaOH or 1M HCl. Final volume
brought to 1000mL total, then solution immediately filtered. 0.1M glucose solution was
prepared using 100mL prepared minimal media with 1.802g dextrose and filtered. Concentration
formula, V1C1=V2C2 V1(0.1M C6H12O6) = (V2 mL)(C2 C6H12O6), was applied to determine
quantities of high-concentration glucose media required to prepare 4mM and 25mM glucose
media preparations, respectively. 200mM glutamine solution was diluted into prepared glucose
conditions using concentration formula to produce 0.7mM glutamine.
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Cell Partitioning/Distribution

Cells were trypsinized and collected in a 50mL conical tube and quenched in 3x volume of
DMEM 10% FBS, then centrifuged at 1100 g for 5 minutes to form a pellet. After
centrifugation, supernatant was aspirated, and cells resuspended in 2mL DMEM by trituration.
Cell concentration was determined using a BioRad TC10 cell counter and dual chamber counting
slides (BioRad). Cell count provided by the TC10 enabled concentration determination by
number of cells/mL; using C1V1=C2V2, the volume necessary to transfer 8.3*103 cells/cm2 from
the concentrated cell suspension to new 10cm diameter dishes (TPP). The concentrated cell
solution was transferred to the 10cm dish pre-dispensed with sufficient media to bring final
volume of DMEM to 10mL.

Experimental Conditions

Each experiment involved two sets of conditions, untreated and treated with 20nM
rapamycin. Each set was initially prepared the same, with 8.3*103 cells/cm2 distributed per
10cm dish into DMEM 10% FBS 25mM glucose 2mM glutamine media and allowed to seat for
24 hours. In each set, media was then aspirated and replaced, with one dish receiving DMEM
growth media, the second dish 25mM glucose/0.7mM glutamine minimal media, and third dish
4mM glucose/0.7mM glutamine minimal media, respectively. The dishes were then allowed to
accommodate to new media conditions for 24 hours. Following this step, 100mM rapamycin
was added to the media in the rapamycin-treated set of dishes to yield a 20nM concentration; the
cells in both conditions were then incubated for an additional 24 hours. After a total of 72 hours
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preparation, the cells, whether in 96-well plate, 6-well plate or 10cm tissue culture dishes were
prepared for experimental assay.

Cell Proliferation Assay

Cells were harvested via trypsinization, counted in a BioRad TC10 cell counter, and distributed
5000 cells/well with a multichannel pipette into a 96 well plate. Cells were given a 12 hour
period to seat in DMEM media, following which the DMEM was aspirated and replaced with
fresh DMEM, 25mM and 4mM in untreated conditions and with fresh DMEM, 25mM, 4mM
containing 20nM rapamycin for treated conditions. Cells were then allowed to incubate at 5%
CO2 37 C in these new conditions for 24 hours. Cell proliferation/cytotoxicity was evaluated
using a colorimetric CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega).
Each well contained 100μL culture media, to which 20μL MTS reagent was added and incubated
at 5% CO2 37 C for two hours. The resulting absorbance was then recorded at 490nm using an
EnVision Multilabel Reader (PerkinElmer).

ATP Quantification

Cells were prepared in 6-well dish as described in the Experimental Conditions section.
Cells were trypsinized, quenched, centrifuged at 1100 rpm for 5 minutes, aspirated and
resuspended in 1mL appropriate media and counted using a BioRad TC10 cell counter. A
multichannel pipette was then used to distribute 5000 cells/well into a black 96-well plate, in
triplicate per condition, with final volume of well brought to 100μL total with the condition24

appropriate media. An ATPlite ATP detection assay system set of reagents were used to
determine ATP concentration by luminescence (PerkinElmer); luminescence was recorded by an
EnVision multiplate reader (PerkinElmer).

Isolation of Mitochondria
Cells were prepared as described in Experimental Conditions, with production scaled to
yield a minimum of 10*106 cells per condition. Cells were trypsinized, quenched in 3x volume
of DMEM 10% FBS, then centrifuged at 1100 g for 5 minutes to form a pellet. Media was
aspirated from the pellets, which were resuspended in 2mL fresh media of the same composition
as incubation; if rapamycin treated, rapamycin was present at 20nM. The cells were then
counted using TC10 cell counter to determine total cell count. The smallest count of total cells
amongst the conditions established the total cell number cap for all conditions. The cell
suspensions were then dispensed to 2mL microcentrifuge tubes, maintaining equal cell count
totals across conditions according to the cell number cap, and brought to 2mL volume with PBS.
The microcentrifuge tubes were then centrifuged at 700 g for 2 minutes. Media/PBS was then
aspirated and cells triturated in PBS and re-centrifuged at 700g for another 2 minutes. Cells
were then prepared with a Mitochondria Isolation Kit for Mammalian Cells (Thermo Scientific),
in accordance with the supplied protocol.
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Citrate Synthase Assay

Mitochondria harvested from each respective condition, as per the Isolation of Mitochondria
step, using the Mitochondria Isolation Kit for Mammalian Cells, were then prepared for a citrate
synthase assay according to an Oroboros Instruments Laboratory Protocol82. Mitochondrial
activity was assayed by dispensing 25μL of mitochondria suspension in an incubation medium
composed of 775μL deionized H2O, 100 μL 0.1mM DTNB, 25 μL 10% Triton X-100, 50 μL
oxaloacetate and 25μL acetyl CoA (AcCoA). Absorbance changes representative of the
enzymatic activity of citrate synthase was then recorded using a Beckman Coulter DU800
spectrophotometer. Mitochondrial membrane integrity was similarly evaluated using an
incubation medium consisting of 800μL H2O, 100μL DTNB, 50μL oxaloacetate, 25μL
mitochondrial suspension, and 25μL AcCoA.

Western Blots
Aliquots of total cell lysates containing 60μg protein were dispensed into sodium dodecyl
sulfate-polyacrylamide gel and subjected to electrophoresis. After electrophoretic separation, the
proteins were then electro-blotted onto nitrocellulose membranes (GE, Hybond –ECL).
Blocking was performed with 5% non-fat milk in TBS with 0.1% Tween, or 5% BSA in TBS
with 0.1% Tween for phosphoproteins. Membranes were probed with primary antibodies
including p-Akt473, p-mTORSer792, and β-actin from Cell Signaling, with p-70S6K from
Millipore. Secondary antibodies used included HRP-conjugated mouse and rabbit antibodies
(manufacturer and concentrations) and LI-COR IR Dye 680 goat and rabbit antibodies and IR
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Dye 800 mouse antibodies, all used at 1:30,000 concentrations. Near-infrared fluorescent
western blots were imaged using an Odyssey Imaging System (LI-COR), and rendered into semiquantitative charts using Image Studio software in conjunction with GraphPad Prism.

CHAPTER THREE: RESULTS
Reduction of formazan product in proliferation assays in rapamycin-treated conditions
The CellTiter Cell Proliferation Assay used to qualitatively evaluate changes in cell
proliferation per growth condition uses a novel tetrazolium compound (MTS) that is presumed to
be intracellularly bioreduced by NADH or NADPH, thus converting the MTS into a formazan
product that absorbs at 490nm83. Due to the area constraint of the 96-well plate, the
preconditioning of cells to new media conditions step was eliminated, opting to simultaneously
treat cells with new media conditions plus rapamycin treatment, instead of sequentially. This
step appeared vital to generating useable absorbance readings within the tolerances of the reagent
and multiplate reader; by restricting the cell population per well, excess formazan production
was prevented.
In each of the experimental replicates, the rapamycin-treated conditions exhibited
reduced absorbances, attributable to reduced formation of formazan product. In the data
supplied by Figure 1, the DMEM, 25mM and 4mM rapamycin conditions had absorbances
reduced by 32% ±6.7%, 25%±7.4% and 20%±3.5%, respectively.
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These results appeared to be in line with Ramanathan and Schreiber’s observation of
rapamycin-induced reduction of glycolysis, which would correlate with reduced proliferation.
However, cells that rely on aerobic glycolysis as an energy currency/building block generator
also have lactate dehydrogenase converting pyruvate and oxidizing NADH to NAD+ 1. A
metabolic system primed for oxidizing NADH may provide a case for a false positive
interpretation of diminished cellular proliferation. Given conditions of lactic acid fermentation,
less NADH is available to reduce MTS to formazan; therefore induced metabolic changes may
alter absorbance without necessarily correlating to cellular proliferation differences.
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0
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25mM
4mM
Media Glucose Concentrations

Figure 1: Absorbance Readings of MTS/Formazan Post Rapamycin Treatment at 490nm
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Increased ATP concentrations in rapamycin-treated conditions
To examine the effect of nutrient restriction and rapamycin treatment on intracellular
energy currency, an assay for quantifying sample ATP concentrations was performed. Following
the procedures outlined in Experimental Conditions, six conditions were prepared in a multiwell
plate and then assayed according to the ATP Quantification protocol. As per the experimental
setup, three media conditions were used: DMEM growth media (25mM glucose, 2mM
glutamine), and minimal media at glucose concentrations of 25 and 4mM, respectively, with
glutamine concentrations of 0.7mM in each. The growth media condition was used as a contrast
in order to compare the ATP concentrations found in each respective media condition, both
untreated and treated with 20nM rapamycin.
Decreases in ATP concentrations were found in the untreated minimal media
concentrations with reduced glutamine, with respect to the DMEM growth media. Additionally,
a decrease in intracellular ATP concentration was observable in the 4mM minimal media versus
the 25mM. Notably, each media condition treated with rapamycin was found to have an
increased ATP concentration versus the untreated conditions. This result appeared to contradict
Ramanathan and Schreiber’s observation that treatment of cells with rapamycin decreased
intracellular ATP concentrations immediately after treatment, and for a brief observation period
thereafter69. Replicate experiments confirmed the repeatability of this phenomenon, thus raising
the question of the source of the ATP generation. In the same article, Ramanathan and Schreiber
observed that rapamycin-treated cells significantly increased the uptake of amino acids readily
converted to TCA intermediates. This information supplied the rationale for the next step: to
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evaluate TCA/OXPHOS as a potential candidate for the increase in intracellular ATP in the
rapamycin-treated cells.
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Figure 2: Molar ATP per Sample, Untreated vs. Treated

Increased specific activity of citrate synthase in rapamycin-treated conditions
A test for indicating increases in mitochondrially-mediated increases in intracellular ATP
via TCA/OXPHOS was derived from an Oroboros Course on High-Resolution Respirometry82.
This assay required the isolation of mitochondria from cells that were processed according to the
Experimental Conditions outlined above, followed by the Isolation of Mitochondria protocol.
Thereafter, the isolated mitochondria were assayed using spectrophotometry to observe the
activity of citrate synthase, in both lysed and unlysed mitochondrial states. Citrate synthase
enacts the first enzymatic step of the TCA, via a conversion of oxaloacetate and acetyl CoA into
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citrate and CoASH: Oxaloacetate + Acetyl CoA → Citrate + CoASH. This assay coupled the
citrate synthase generation of citrate and CoASH with the reaction of CoASH and a reactive
substrate DTNB, as follows: CoASH + DTNB → DTNB-CoA. Specific activity could then be
quantified by monitoring the formation of DTNB-CoA, absorbs at 412nm82.
The formula for calculating specific activity, ν:

, where rA = dA/dt,

the rate of absorbance change min-1; l, optical path length = 1 cm; εB, extinction coefficient of B
(DTNB) at 412 nm and pH 8.1 = 13.6mM−1⋅cm−1; νB, stoichiometric number of B (TNB) in the
reaction = 1; Vcuvette, volume of solution in the cuvette = 1000 μl; Vsample, volume of sample added
to cuvette (100 μl, 25 μl, 5 μl); ρ, mass concentration or density of biological material in the
sample, either protein concentration: mg⋅cm-3 or cell density: 106⋅cm-3 82. Both protein
concentration and cell density were used as factors for ρ in calculating specific activity; with
both factors resulting in similar proportions with small variations in total IU per 106 cells or
protein concentrations, respectively. Results were reported in cell density format, as cell count
was deemed more reliable an index for ρ. Bradford assays using total cell lysates from the
Isolation of Mitochondria procedure yielded significant variations in protein concentration across
replicates, likely attributable to inhomogeneous lysis of cell samples occurring in this step.

Similar to the ATP Quantification experiments, six conditions were tested. However, the
DMEM untreated and treated conditions exhibited considerable variability in the quantified
citrate synthase specific activity. This variability has been hypothesized to be attributable to the
presence of factors present in DMEM but missing in the prepared minimal media. Thus, the
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DMEM results have been excluded as a contrast for the 25mM and 4mM minimal media
conditions. Despite the variability introduced through artifact in the DMEM conditions,
increased specific activity of citrate synthase was observed in both rapamycin-treated minimal
media conditions in contrast to the untreated conditions.
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Figure 3: Mitochondrial Activity Assay, Citrate Synthase Specific Activity in International Units/106 cells

The above experiment assayed for total citrate synthase activity; combined with this
assay was an additional spectrophotometric test for mitochondrial membrane integrity. This
assay required placement of the isolated mitochondria into a reagent matrix of very similar
composition to the activity assay, but eliminated the Triton X-100. By removing detergent from
the matrix, the relative integrity of the mitochondrial membranes could be evaluated by the
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increases in absorbance due to the permeability/leakiness of the membranes. These experiments
indicated that the rapamycin-treated mitochondrial membranes may exhibit slightly lower
permeability/leakiness that the untreated conditions; however, due to bounds of measurement
error and the minuteness of the measurements, these results remain of indeterminate value.
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Figure 4: Mitochondrial Integrity Assay, Citrate Synthase Specific Activity in International Units/10 6 cells

Western immunoblots
A series of Western Immunoblots were generated from lysates prepared from cells
cultured according to the Experimental Conditions procedure and probed with primary
antibodies that would provide insight into the changes of expression and phosphorylation of
various metabolic and proliferative proteins. The first of the proteins probed was phospho33

p70S6k, a downstream effector of mTORC1, in order to determine if rapamycin-mediated
inhibition of mTORC1 reduced phosphorylation and activation of this key translational protein.

Figure 5: phospho-70S6 kinase Western immunoblot, β-actin control. p70S6k above, β-actin below. D =
DMEM, 25 = 25mM, 4 = 4mM, DR = DMEM plus rapamycin, 25R = 25mM plus rapamycin, 4R = 4mM plus
rapamycin.
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Figure 6: Semi-quantitative densitometry of phospho-S6 kinase. From left to right in Untreated category:
DMEM, 25mmM, 4mM media glucose conditions; in Rapamycin category, DMEM, 2mmM, 4mM all treated with
20nM rapamycin.
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After normalizing the luminescence values of p70S6K to the β-actin luminescence
readings, a number of differences were noted intra-category and between the untreated and
treated categories. Firstly, a slight reduction S6K phosphorylation was noted in the untreated
category between the growth media DMEM and the 25mM minimal media. A striking
difference, however, was noted between the phosphorylation levels of S6K in the 4mM versus
the higher glucose concentration media. The 4mM minimal media, untreated, showed nearly a
third of the phosphorylation level of S6K compared to the DMEM and 25mM minimal medias.
In the rapamycin-treated category, both high glucose media exhibited very weak phosphorylation
signals, indicating the inhibitory effect of rapamycin treatment on the phosphorylation of S6K.
Notably, the 4mM minimal media treated with rapamycin also showed reduction of
phosphorylation compared to untreated conditions, but retained more ~5-10x more
phosphorylation of S6K versus the 25mM and DMEM treated conditions, respectively.
The next primary probed was phospho-Akt (Ser 473). In the untreated category, the
growth media condition showed much less phosphorylation relative to the 25mM and 4mM
media conditions. In the treated category, an increase of phosphorylation was noted in the
growth media condition, with decreases of phosphorylation observed in both 25mM and 4mM
compared to the untreated conditions.
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Figure 7: phospho-Akt (Ser 473), β-actin control. Phospho-Akt above, β-actin below. D = DMEM, 25 = 25mM,
4 = 4mM, DR = DMEM plus rapamycin, 25R = 25mM plus rapamycin, 4R = 4mM plus rapamycin.
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Figure 8: Semi-quantitative densitometry of phospho-Akt (Ser473). From left to right in Untreated category:
DMEM, 25mmM, 4mM media glucose conditions; in Rapamycin category, DMEM, 2mmM, 4mM all treated with
20nM rapamycin.

Another vantage on the activity of cell line response to nutrient restriction/rapamycin
treatment was provided by the mTORC1-associated protein, Raptor. Raptor is phosphorylated
by AMPK on serine residues 722 and 792, which induces inhibition of mTORC1 activity; this
phosphorylation occurs in response to AMPK sensing high AMP concentrations relative to
ATP84. In the untreated conditions, there appeared to be more regulation/inhibition of mTORC1
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activity via inhibition of Raptor (Ser792) in the DMEM condition, with less phosphorylation of
the residue in both 25mM and 4mM conditions. Paradoxically, in the treated conditions, the
4mM glucose media showed the highest phosphorylation of Raptor, with the DMEM showing
negligible and the 25mM condition severely reduced phosphorylations, respectively.

Figure 9: phospho-Raptor (Ser 792), β-actin control. Phospho-Raptor above, β-actin below. D = DMEM, 25 =
25mM, 4 = 4mM, DR = DMEM plus rapamycin, 25R = 25mM plus rapamycin, 4R = 4mM plus rapamycin.

Normalized phospho-Raptor (Ser 792)

Fluorescence

1500

D
25mM
4mM

1000

500

U

Tr
ea
te
d

nt
re
at
ed

0

Treatment Conditions

Figure 10: Semi-quantitative densitometry of phospho-Raptor (Ser792). From left to right in Untreated
category: DMEM, 25mmM, 4mM media glucose conditions; in Rapamycin category, DMEM, 2mmM, 4mM all
treated with 20nM rapamycin.
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CHAPTER FOUR: DISCUSSION
The transgenic P177 myristoylated Akt1 cell line sourced from a murine pancreatic lesion
provided a model to evaluate the in vitro effects of sequential nutrient restriction and inhibition
of mTORC1 on proliferation, expression and metabolism. This cell line offered an opportunity
to investigate and potentially manipulate altered cell metabolism in a hyperactivated Akt context,
a simulated condition that has been reported in many cancer types. Akt is particularly important
in the deregulation of metabolism, factoring importantly in aerobic glycolysis; upon activation,
Akt translocates to mitochondria and may contribute to the stimulation of aerobic glycolysis via
activation of downstream effectors, such as the phosphorylation of HK II85,86. Additionally, Akt
figures importantly in the activation of mTOR, which has also been reported to directly control
mitochondrial respiration69.

An inhibitor of the Akt/mTOR pathway, rapamycin, was used to evaluate the differences
in metabolic activity across a set of nutritional conditions. Similarities were observed in the
rapamycin-treated conditions with respect to the untreated 4mM glucose minimal media. In
particular, reduced phosphorylation of S6K was observed, a key translational protein whose
down-regulation would adversely affect proliferation. All rapamycin-treated conditions showed
significant de-phosphorylations of p70S6K, with varying responses associated with the
nutritional richness of the corresponding media. In particular, rapamycin treatment was
associated with reduced phosphorylation of S6K in the higher glucose concentration media
compared to the 4mM, reduced glutamine media formula.
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The 4mM glucose media formula demonstrated an additional difference when treated
with rapamycin, with respect to the phosphorylation status of Raptor (Ser792). Where the
DMEM and 25mM treated conditions showed very low to negligible phosphorylation of this
residue, the 4mM condition did show phosphorylation, though reduced in contrast to the
untreated condition. Most importantly, all treated conditions demonstrate a reduced
phosphorylation of Raptor (Ser792), which indicates a reduction of Raptor inhibition. In
conditions where mTORC1 is inhibited, the reduced inhibition of Raptor by AMPK in higher
glucose concentrations may indicate that a compensatory mechanism bypasses the allosteric
effects of rapamycin on mTORC1 function. The phosphorylation of Raptor (Ser792) in the
4mM condition, conversely, appears paradoxical, in that the low glucose conditions would
ostensibly be more conducive to a starvation state where the cell has an increased supply of AMP
relative to ATP.

Expression differences in phospho-Akt were also noted; probing for this activated protein
revealed an apparently additive effect of reduced nutrient supply in combination with rapamycin
treatment. Comparing the semi-quantitative data obtained from the Western immunoblots
showed that the untreated 4mM media had lower phospho-Akt compared to the 25mM media.
Furthermore, both prepared media exhibited reduced phospho-Akt, compared to untreated
conditions, when treated with rapamycin. DMEM growth media showed reduced phospho-Akt
in contrast to both 25mM and 4mM prepared media conditions, though phospho-Akt increased
with rapamycin treatment, relative to the untreated growth media condition. This phenomenon
may be explained by the upregulation of Akt as an adaptive response to foreign conditions. The
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change from the nutritional excess of the growth media DMEM formulation to the minimal
media preparations would require some physiological adjustment on the part of the cell; this
response may also account for the increase of phospho-Akt in the growth media conditions due
to stress induced by rapamycin treatment. For this reason, cells were preconditioned to new
media conditions for a period of 24 hours. This interval provided time for adaptation and
allowed the adaptive response to attenuate as the cells equilibrated with the new environment.
Additionally, Akt may still be phosphorylated on the Ser473 residue by mTORC2, which is
insensitive to rapamycin, or another phosphoinositide dependent kinase 2, such as integrin-linked
kinase or p21-activated kinase92.

The results of the ATPlite experiments revealed consistent differences in ATP
concentrations in untreated versus treated cells across nutritional conditions. The increased
concentrations of ATP found in the rapamycin-treated conditions contradicted Ramanathan and
Schreiber’s finding that rapamycin treatment significantly lowered intracellular ATP
concentrations immediately and for up to 25 minutes post-treatment. The hypothesis of this
study was based on an expectation that the treated cells would respond similarly to rapamycin
and decrease production of ATP. A combination treatment of reduced glucose followed by a
reduction of ATP production seemed like a favorable situation to induce an energetic crisis in
cells reliant on aerobic glycolysis. In Direct control of mitochondrial function by mTOR, the
authors state: “Inhibiting mTOR…enhances aerobic glycolysis, but also induces a state of
increased dependence on aerobic glycolysis in leukemic cells.” The contradictory results of
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increased ATP concentrations raises additional questions regarding the expectation underlying
the hypothesis, as well as the results of Ramanathan and Schreiber’s study69.

The increased concentrations of ATP after 24 hours of treatment suggested that some
alteration in the metabolic system of the cells resulted from rapamycin treatment. A variety of
metabolic mechanisms could be responsible for these results; the next step was to identify the
potential source of the increased ATP. As TCA/OXPHOS is a much more efficient generator of
ATP compared to glycolysis, this pathway seemed like a promising candidate to investigate
metabolic changes. Also, Ramanathan and Schreiber noted that cells treated with rapamycin
began to increase uptake of amino acids that are readily converted to TCA intermediates69. In
order to probe the possibility of increases in the TCA/OXPHOS pathway, the citrate synthase
specific activity procedure was applied to all conditions.

Consistent results reporting increased specific activity of citrate synthase in rapamycintreated minimal media conditions suggest an increase TCA/OXPHOS pathway activity.
However, a response deriving from the TCA/OXPHOS pathway does not indicate an induced
metabolic switch from aerobic glycolysis to aerobic respiration. This condition may result as an
indirect effect of rapamycin treatment, with alternate energetic pathways compensating for an
energy currency deficit. A down-regulation of aerobic glycolytic activity, for example, would
generate a different proportion of glycolytic intermediates which could then be consumed by
TCA/OXPHOS.
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For the purposes of this study, targets immediately upstream and downstream of
mTORC1 were selected for analysis. An exhaustive analysis of the signaling pathways could not
be accomplished here; however, there are compelling candidates that have been implicated in the
signaling/metabolic pathways. For example, inhibition of mTOR has been reported to downregulate the expression of glycolytic isoenzyme PKM281,88. Reduced expression of PKM2 may
consequentially result in increased expression of PKM1, which has a faster reaction rate in
generating pyruvate, thus reducing glycolytic intermediate supply for conversion into building
blocks. Also, increased production of pyruvate by the higher reaction rate PKM1 would increase
available substrate for TCA/OXPHOS.

mTORC1 inhibition has also been shown to induce up-regulation of a microRNA in
human cell lines, miR-143; upregulation of miR-143 has been shown to accompany downregulation of HK II in a variety of mouse and human cancer cell lines89,90. A recent study using a
human pancreatic cell line (Panc-1) induced an increase in miR-143 and a corresponding
decrease in HK II by inhibiting mTORC1 with a rapamycin analog, everolimus. Additionally,
Panc-1 cells treated with everolimus demonstrated lower levels of lactate dehydrogenase activity
and lactate production versus untreated cells. The authors conclude that inhibition of mTORC1
signaling results in an inhibition of glycolysis91. Such a conclusion, however, oversimplifies the
complexity of the cellular expression response to mTORC1 inhibition. Reduced turnover rate of
pyruvate may result from higher Km hexokinase isoenzymes that are expressed in compensation
to the miR-143 inhibited HK II. Such a result does not necessarily correspond to inhibition of
glycolysis, instead potentially reflecting an expression-induced change of rate.
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The fact that increased ATP is observed in contradistinction to Ramanathan and
Schreiber’s observation of decreased ATP as an immediate response to rapamycin exposure may
indicate that the above authors captured a transitional step in metabolic switching in response to
mTOR inhibition. The discovery of miR-143-mediated down-regulation of glycolysis offers
support for this possibility. In particular, the decrease of lactate dehydrogenase (LDH) activity
in the everolimus-treated Panc-1 cells suggests a reversion of the glycolytic pathway from
aerobic to typical glycolysis. With less LDH activity converting pyruvate to lactic acid, a greater
supply of pyruvate would remain available as substrate for mitochondrial conversion via
TCA/OXPHOS.

The results of the experiments listed for this study do not readily conform to the
expectations of the proposed hypothesis: a combination treatment of nutrient restriction and
rapamycin inhibition will exert an additive or synergistic cytostatic/cytotoxic effect in vitro on
the mAkt1 pancreatic early lesion cell line. What seems probable, given the results and with new
information about the effects of miR-143, is a situation of reduced cellular proliferation in cells
exhibiting aerobic glycolysis when treated with rapamycin. Restriction of nutrients in
combination with inhibition of mTOR signaling seems likely to further reduce proliferation due
to reduced supply of building blocks. This reformulated proposal can be tested using
carboxyfluorescein succinimidyl ester (CFSE) dye in conjunction with flow cytometry. Another
proposal is to identify the mechanisms responsible for metabolic conversion, discerning if a
conversion from aerobic glycolysis to typical glycolysis occurs in response to mTOR inhibition.
This could be tested by quantifying glycolysis reaction rate and identifying isoenzyme
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expression with respect to treatment conditions. Lastly, changes can be tracked in
TCA/OXPHOS activity as a response to mTOR inhibition and varying nutrient conditions.

CHAPTER FIVE: CONCLUSION
In summary, nutrient restriction in vitro appears to exert some similar effects to
rapamycin-mediated inhibition of mTORC1. Nutrient availability, glucose and glutamine in
particular, impacts phosphorylation states of S6K, and consequently processes of translation.
The increases in ATP concentration may potentially be attributable to an increase in
TCA/OXPHOS; the increased citrate synthase activity provides a suggestive clue to this
possibility. However, the increased specific activity of this enzyme does not conclusively
demonstrate the switching of metabolic emphasis from glycolysis to TCA/OXPHOS. Thus, a
necessary future direction is to directly monitor the extracellular acidification rate (ECAR )and
oxygen consumption rate (OCR) of the six defined conditions to determine if a metabolic
switching occurs in the process of rapamycin treatment, and if nutrient restriction additively or
negatively contributes to such a conversion.

Future Directions
The measurement of ECAR and OCR per condition will be necessary to determine if the
increased source of intracellular ATP can be attributed to increased mitochondrial function. This
step will be performed with a Seahorse Biosciences XFe24 extracellular flux machine, and tested
with a glycolysis stress kit.
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Confirmatory results of reduced proliferation with respect to nutrient conditions intracategorically, and also versus rapamycin-treated conditions can be more accurately assessed
using carboxyfluorescein succinimidyl ester (CFSE), a fluorescent dye used in flow cytometry to
quantify cell proliferation. Upon cellular uptake and modification of this dye, CFSE cannot
readily leave the cell. As a result, upon cellular division, the dye is distributed between daughter
cells. Peak fluorescent intensity supplies information on the degree of proliferation that has
occurred; high intensity peak indicates low proliferation, lower intensity, with a broader
distribution or peak area indicates increased proliferation. This test would provide significantly
improved quantitation of reduced proliferation in either nutrient-restricted or rapamycin-treated
conditions.
Western blots will also be generated showing total AKT, total S6K and total Raptor in
order to relate expression levels to phosphorylation levels.
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